. Author manuscript; available in PMC: 2019 Jul 15.

Published in final edited form as: J Enzyme Inhib Med Chem. 2016 Jul 17;31(SUP2):148–161. doi: 10.1080/14756366.2016.1193734

Table 4.

C_max,u / IC₅₀ values for inhibitors of tazarotenic acid sulfoxidation. C_max and f_u data compiled from literature references as noted in the Materials and Methods.

					C_max,u/IC₅₀

Inhibitor	Oral Dose	C_max (nM)	f_u,plasma	C_{max, u} (nM)	CYP 26A1	CYP 26B1
Benzbromarone	100 mg	9236	0.010	92.4	0.147	0.012
Candesartan	16 mg QD	270	0.002	0.38	< 0.001	< 0.001
Clotrimazole	1% Topical	67300^*	0.100	6730	337	135
17α-Ethynylestradiol	30 μg	0.5	0.002	0.00085	< 0.001	< 0.001
Fluconazole	200 mg BID	34606	0.890	30794	44.0	1.56
Itraconazole	200 mg QD	919	0.002	1.80	0.003	0.011
Mometasone	50 μg Inhaled	0.05	0.010	0.0005	< 0.001	< 0.001
Montelukast	10 mg	925	0.010	8.90	0.077	0.015
Pioglitazone	45 mg	4489	0.010	38.0	0.048	0.005
Quercetin	500 mg TID	50.9	0.009	0.45	< 0.001	< 0.001
Raloxifene	1 mg/kg	1.05	0.050	0.50	< 0.001	< 0.001
Repaglinide	4 mg	104	0.026	2.60	< 0.001	0.004
Ritonavir	600 mg BID	15258	0.010	150	0.040	0.060
Rosiglitazone	8 mg	1673	0.002	3.40	< 0.001	< 0.001
Tamoxifen	10 mg BID	323	0.020	6.40	< 0.001	< 0.001
Zafirlukast	20 mg BID	1125	0.010	3.00	0.188	0.016

Represents reported clotrimazole concentration in skin (stratum corneum) following topical administration of a 1% clotrimazole cream formulation.